ANSWER: B

Rationale:

Both ciprofloxacin and smoking cessation reduce theophylline clearance through the same mechanistic pathway — CYP1A2-mediated hepatic metabolism — and their effects are additive rather than opposing. Ciprofloxacin is a CYP1A2 inhibitor that reduces theophylline clearance by approximately 30–50% by directly impairing enzyme activity. Smoking cessation removes the polycyclic aromatic hydrocarbon (PAH)-driven CYP1A2 induction that had been sustaining this patient's elevated clearance; this induction wanes progressively over one to two weeks after PAH exposure ceases. When both changes occur simultaneously in a patient whose theophylline dose was calibrated to smoker-level clearance, the result is a compounded reduction in CYP1A2 activity — the enzyme is simultaneously losing its induced baseline expression (cessation effect) and being actively inhibited (ciprofloxacin effect). The potential for a dramatic and dangerous rise in theophylline concentrations from a baseline already at 16 mcg/mL is substantial; toxicity at concentrations of 25–40 mcg/mL or higher is a realistic outcome without proactive management. The appropriate response is immediate theophylline dose reduction combined with urgent serum level monitoring.

• Option A: Option A is incorrect because while both changes affect CYP1A2, they do not oppose each other — they work in the same direction (both reduce clearance and raise theophylline levels); characterizing them as canceling out is pharmacologically incorrect and would lead to dangerous clinical inaction.
• Option C: Option C is incorrect because ciprofloxacin inhibits (not induces) CYP1A2, causing theophylline levels to rise, not fall; increasing the theophylline dose in response to ciprofloxacin addition would compound the toxicity risk rather than counteract it.
• Option D: Option D is incorrect because the CYP1A2-inducing component of tobacco smoke is polycyclic aromatic hydrocarbons, not nicotine; nicotine clearance within 72 hours is irrelevant to CYP1A2 induction, which is driven by PAHs and wanes over one to two weeks — not 72 hours; characterizing smoking cessation's contribution as negligible dramatically understates the clinical significance of the combined interaction.
• Option E: Option E is incorrect because theophylline is only approximately 40% protein-bound and protein binding changes are not the mechanism of the smoking-theophylline pharmacokinetic relationship; theophylline is eliminated primarily by hepatic CYP1A2 metabolism rather than renal tubular secretion, so ciprofloxacin's impact on renal transporters is not the clinically important mechanism; free theophylline monitoring does not substitute for dose adjustment in this scenario.

ANSWER: D

Rationale:

The mechanistic basis for theophylline seizure refractoriness is rooted in adenosine A1 receptor antagonism. In the CNS, adenosine functions as an endogenous inhibitory neuromodulator: A1 receptor activation on neurons produces Gi-protein-mediated inhibition of adenylyl cyclase, reduces calcium influx through voltage-gated calcium channels, increases potassium conductance, and elevates the threshold for action potential generation — collectively suppressing neuronal excitability and providing an endogenous anticonvulsant brake. Theophylline's non-competitive A1 receptor antagonism removes this inhibitory tone, creating a pro-convulsant neurochemical state. Standard anticonvulsants target distinct mechanisms: benzodiazepines enhance GABA-A chloride conductance, levetiracetam modulates SV2A-mediated synaptic vesicle release, and phenytoin blocks sodium channels — none of these directly restores the adenosine-mediated inhibitory tone that theophylline has blocked. Additionally, theophylline-stimulated catecholamine release further raises neuronal excitability. Hemodialysis rapidly removes theophylline from the circulation, progressively restoring endogenous adenosine's A1-mediated inhibitory function and allowing the pro-convulsant state to resolve — making it the most effective intervention for refractory theophylline seizures with a level of 55 mcg/mL.

• Option A: Option A is incorrect because theophylline does not upregulate GABA-A receptor subunit expression as a mechanism of seizure refractoriness; the refractoriness is not receptor-subunit-mediated; and phenytoin is not specifically effective against theophylline-induced seizures — the refractory nature of these seizures extends to multiple anticonvulsant classes including phenytoin.
• Option B: Option B is incorrect because theophylline does not deplete CNS glutamate stores; theophylline-induced seizures reflect increased neuronal excitability through adenosine A1 antagonism and catecholamine release, not glutamate depletion causing paradoxical disinhibition; and hemodialysis terminates seizures by removing theophylline, not by restoring glutamate homeostasis.
• Option C: Option C is incorrect because theophylline-induced seizures are driven by abnormal central neuronal electrical activity, not by peripheral chemoreceptor activation at the carotid body; carotid body stimulation by adenosine antagonism contributes to cardiovascular effects but is not the mechanism of CNS seizure generation; propofol does not address the underlying pharmacological cause and is not the definitive intervention.
• Option E: Option E is incorrect because theophylline does not occupy benzodiazepine binding sites on GABA-A receptors; theophylline is a methylxanthine with no direct affinity for benzodiazepine receptor sites; the refractoriness is mechanistic rather than competitive, and levetiracetam — already administered without full effect in this case — is not reliably effective against theophylline seizures any more than other standard agents.

ANSWER: A

Rationale:

This case illustrates the compounded pharmacokinetic hazard of combining two drugs that inhibit different — but overlapping — CYP isoforms responsible for theophylline metabolism. Theophylline is metabolized primarily by CYP1A2 (more than 90% of clearance) with minor contributions from CYP3A4 and CYP2E1. Erythromycin is a well-established CYP3A4 inhibitor; it reduces theophylline clearance by approximately 25–35% by impairing the minor CYP3A4-mediated pathway. Cimetidine, an H2-receptor antagonist still available over the counter, inhibits both CYP1A2 and CYP3A4 — a broader inhibitory profile that includes the primary theophylline metabolic pathway. Cimetidine alone can increase theophylline levels by 30–70%. When added to erythromycin, cimetidine extends inhibition from CYP3A4 alone to now also encompass CYP1A2, the dominant clearance pathway. The result is multi-isoform suppression of theophylline elimination across both primary and secondary metabolic routes simultaneously, producing clearance reduction well beyond what either agent would cause alone. This mechanistic compounding — not simple addition — explains why the theophylline concentration more than doubled from 14 to 31 mcg/mL within five days. This case also highlights the clinical hazard of over-the-counter cimetidine use in theophylline-treated patients.

• Option B: Option B is incorrect because erythromycin and cimetidine do not share the same mechanism of inhibition: erythromycin inhibits CYP3A4 while cimetidine inhibits both CYP1A2 and CYP3A4; their combination is not a simple doubling of a single pathway's inhibition — it produces multi-pathway suppression that is not arithmetically predictable from single-agent data.
• Option C: Option C is incorrect because theophylline's sustained-release absorption is not meaningfully enhanced by elevated gastric pH from erythromycin; erythromycin does not raise gastric pH substantially; and cimetidine's principal mechanism in this interaction is CYP inhibition, not H2-mediated reduction in renal blood flow — theophylline is eliminated predominantly by hepatic metabolism, not renal excretion.
• Option D: Option D is incorrect because erythromycin does not induce intestinal P-glycoprotein — it actually inhibits P-glycoprotein — and P-glycoprotein modulation does not significantly alter theophylline bioavailability, as theophylline is not a clinically significant P-glycoprotein substrate; cimetidine does not cause competitive protein binding displacement as a mechanism of theophylline toxicity.
• Option E: Option E is incorrect because CYP2D6 is not a significant isoform in theophylline metabolism; the dominant pathway is CYP1A2 with minor contribution from CYP3A4 and CYP2E1; neither erythromycin nor cimetidine acts primarily through CYP2D6 inhibition in this interaction.

ANSWER: C

Rationale:

Switching from montelukast to zileuton in a patient concurrently receiving theophylline triggers a clinically critical drug interaction that demands immediate proactive management. Zileuton inhibits CYP1A2 at clinical concentrations, and CYP1A2 is the primary enzyme responsible for theophylline hepatic metabolism — accounting for more than 90% of clearance. Co-administration of zileuton with theophylline can approximately double theophylline serum concentrations within days; in this patient whose baseline level is 12 mcg/mL, doubling would produce approximately 24 mcg/mL — well within the toxic range. The required response is a proactive theophylline dose reduction of approximately 50% at the time zileuton is initiated, with careful serum level monitoring to confirm concentrations remain therapeutic. The second management imperative is hepatic monitoring: zileuton causes hepatocellular injury in a small but clinically significant proportion of patients, requiring LFT monitoring at baseline, monthly for the first three months, every two to three months for the remainder of the first year, and periodically thereafter; zileuton is contraindicated if LFTs exceed three times the upper limit of normal. The pulmonologist's pharmacological reasoning — that 5-LOX inhibition provides broader leukotriene suppression including LTB4 in eosinophilic polyposis — is clinically sound, but these two monitoring and management actions are non-negotiable prerequisites for safe zileuton use in this patient.

• Option A: Option A is incorrect because zileuton does inhibit CYP1A2 at clinical concentrations — the drug interaction profile is more complex after the switch, not simpler; zileuton does not eliminate the interaction concerns present with montelukast but introduces different and more serious ones including the theophylline interaction and hepatotoxicity monitoring requirement.
• Option B: Option B is incorrect because zileuton's mechanism (upstream 5-LOX inhibition) does not produce incomplete CysLT1 blockade relative to montelukast — it acts differently by reducing leukotriene synthesis entirely rather than blocking the receptor; zileuton is not a therapeutic downgrade in AERD; its broader suppression of both CysLT and LTB4 synthesis is a pharmacological advantage over receptor-selective antagonists, particularly in polyposis with prominent eosinophilic inflammation.
• Option D: Option D is incorrect because zileuton does not induce CYP1A2 — it inhibits it; there is no PXR-mediated CYP1A2 autoinduction mechanism for zileuton that would offset its inhibitory effect; and LFT monitoring requirements are mandated by the FDA prescribing label regardless of whether the patient develops jaundice, since asymptomatic enzyme elevations require discontinuation before symptomatic hepatitis develops.
• Option E: Option E is incorrect because zileuton does not inhibit COX-1; its mechanism is selective 5-LOX inhibition; COX-1 inhibition is the mechanism of aspirin and non-selective NSAIDs that trigger AERD; zileuton is neither pharmacologically related to COX inhibitors nor contraindicated in AERD — it is specifically effective in AERD by suppressing the leukotriene overproduction that COX-1 inhibition unleashes.

ANSWER: E

Rationale:

The FDA's March 2020 boxed warning for montelukast does not create an absolute contraindication but establishes a mandatory, individualized benefit-risk evaluation. The warning is most actionable in patients with mild disease where effective alternatives exist — precisely this patient's situation for her allergic rhinitis component, where intranasal corticosteroids and antihistamines could be further optimized before adding montelukast. Her prior major depressive disorder represents a clinically important modifier: patients with a psychiatric history may be at heightened vulnerability to montelukast-related neuropsychiatric events, and the recurrence of depressive symptoms on montelukast — which could be misattributed to relapse rather than drug effect — poses a real clinical hazard. The appropriate framework is: document the individualized benefit-risk discussion; verify that rhinitis alternative therapies have been genuinely maximized; if montelukast is chosen, provide detailed and specific counseling on neuropsychiatric symptoms; establish close follow-up; and create an explicit, documented plan for discontinuation if mood changes, sleep disturbance, anxiety, or depressive symptoms emerge. Montelukast remains an option for this patient — it is not forbidden — but the decision requires more clinical deliberation than it would for a patient without psychiatric history.

• Option A: Option A is incorrect because the boxed warning explicitly applies to all age groups, including adults; age alone does not determine the risk profile, and established psychiatric history in an adult is precisely the type of clinical context the warning highlights as requiring careful individual assessment.
• Option B: Option B is incorrect because sertraline does not dramatically inhibit CYP2C8 to a degree that constitutes a formal montelukast contraindication or requires dose reduction; sertraline has modest CYP interactions but the montelukast-sertraline combination does not carry a pharmacokinetic dose adjustment requirement in FDA labeling; the principal concern with this combination is pharmacodynamic (additive neuropsychiatric risk), not pharmacokinetic.
• Option C: Option C is incorrect because the boxed warning does not establish an absolute contraindication for patients with any prior psychiatric history; it requires individualized benefit-risk assessment and informs prescribing decisions — particularly around avoiding montelukast as first-line therapy for mild disease where alternatives exist — but it does not categorically prohibit its use in patients with remitted depression.
• Option D: Option D is incorrect because zafirlukast does not carry the neuropsychiatric boxed warning, but it is not the appropriate comparator here — its twice-daily empty-stomach dosing and warfarin interaction profile create different clinical burdens; furthermore, the reasoning that zafirlukast is automatically preferred over montelukast in any patient with psychiatric history overstates the implications of the warning and misapplies the FDA guidance, which is about benefit-risk evaluation, not drug substitution mandates.

ANSWER: B

Rationale:

This case demonstrates compounded CYP2C9 inhibition producing a clinically dangerous amplification of warfarin anticoagulation. S-warfarin, the pharmacologically more potent enantiomer, is metabolized primarily by CYP2C9. Zafirlukast inhibits CYP2C9 at clinical concentrations — this is the basis of its well-documented warfarin interaction requiring INR monitoring whenever zafirlukast is initiated in warfarin-treated patients. In this patient, zafirlukast was already elevating warfarin exposure relative to what the stable pre-zafirlukast dose would have produced. Fluconazole is a potent inhibitor of both CYP2C9 and CYP3A4 and is one of the most clinically significant CYP2C9 inhibitors in routine practice; it can dramatically raise S-warfarin concentrations when added to stable warfarin therapy. When fluconazole is added to a patient already receiving zafirlukast — which is itself suppressing CYP2C9 — the residual CYP2C9 activity is further reduced by fluconazole's inhibitory action on the same enzyme, producing compounded suppression of S-warfarin clearance and a dramatic INR rise from 2.4 to 5.8. The interaction is clinically predictable and potentially avoidable with INR monitoring at the time antifungal therapy is initiated.

• Option A: Option A is incorrect because while fluconazole does inhibit CYP3A4, and zafirlukast is partially metabolized by CYP2C9 (rather than CYP3A4 being its primary metabolic enzyme), the mechanism described — fluconazole raising zafirlukast concentrations to amplify zafirlukast's CYP2C9 inhibition — is a plausible but secondary pathway; the primary and dominant mechanism is direct dual CYP2C9 inhibition of warfarin clearance by both agents simultaneously, not a sequential cascade through zafirlukast accumulation.
• Option C: Option C is incorrect because protein displacement is not a clinically significant mechanism for either of these drug interactions; warfarin is not primarily cleared by renal organic anion transporters; and hepatic CYP metabolism — specifically CYP2C9 — is the principal determinant of warfarin clearance and the mechanistic basis for both interactions.
• Option D: Option D is incorrect because neither zafirlukast nor fluconazole directly inhibits vitamin K epoxide reductase; warfarin is the vitamin K epoxide reductase inhibitor; the interactions in this case are pharmacokinetic (CYP2C9 inhibition raising warfarin plasma concentrations), not pharmacodynamic (direct coagulation enzyme inhibition).
• Option E: Option E is incorrect because fluconazole's warfarin interaction is mediated primarily through CYP2C9 (and to a lesser extent CYP3A4) inhibition, not CYP1A2 inhibition; zafirlukast is not metabolized by N-deacetylation through CYP1A2 as its primary pathway; and warfarin absorption is not inhibited by zafirlukast accumulation — the mechanism described is pharmacologically inaccurate.

ANSWER: D

Rationale:

This question requires synthesizing AERD pathophysiology, aspirin desensitization pharmacology, and gastrointestinal COX-1 pharmacology across two organ systems. Aspirin desensitization is pharmacologically feasible in a patient with prior PUD that has been successfully treated — H. pylori eradication and healed mucosa substantially reduce but do not eliminate ulcer recurrence risk. The procedure itself uses graded oral aspirin starting at very low doses (30–60 mg), with incremental increases monitored in a controlled setting; this portion carries manageable procedural GI risk. The maintenance phase, however, presents a genuine and clinically important pharmacological hazard: maintaining the desensitized state requires continuous aspirin at 325–650 mg twice daily — doses that substantially inhibit COX-1-mediated prostaglandin E2 and prostacyclin (PGI2) synthesis in the gastric mucosa. PGE2 and PGI2 are the principal prostaglandins responsible for maintaining gastric mucosal integrity through stimulating mucus and bicarbonate secretion, maintaining mucosal blood flow, and inhibiting acid secretion; their suppression by high-dose aspirin maintenance directly increases peptic ulcer recurrence risk. Planned co-therapy with a proton pump inhibitor (PPI) is the standard approach to managing this risk in patients with prior PUD who require long-term high-dose aspirin.

• Option A: Option A is incorrect because prior PUD that has been successfully treated with H. pylori eradication and confirmed mucosal healing is not an absolute contraindication to aspirin desensitization; and aspirin at maintenance doses does not provide gastroprotection through paradoxical COX-1-mediated prostaglandin induction — COX-1 inhibition at these doses suppresses, not induces, gastric prostaglandins.
• Option B: Option B is incorrect because aspirin desensitization is performed via graded oral aspirin challenge, not IV aspirin lysinate administration; IV aspirin lysinate is not the established protocol for aspirin desensitization in AERD; and prior PUD with successful treatment is not a formal absolute contraindication to the procedure.
• Option C: Option C is incorrect because the challenge phase does use doses that begin at 30–60 mg and escalate — by the end of the challenge, full anti-inflammatory aspirin doses (325 mg or higher) are administered, which do inhibit COX-1-mediated gastric prostaglandin synthesis; and maintenance doses of 325–650 mg twice daily are substantial COX-1 inhibitors that meaningfully suppress gastric mucosal prostaglandins, creating real ulcer recurrence risk.
• Option E: Option E is incorrect because the AERD mechanism does not provide gastroprotection; cysteinyl leukotriene suppression during desensitization maintenance does not paradoxically upregulate COX-1-mediated gastric prostaglandin production; the two pathways are mechanistically independent at the gastric level, and aspirin's COX-1 inhibition in the gastric mucosa suppresses protective prostaglandins regardless of the patient's leukotriene biology.

ANSWER: A

Rationale:

The pharmacological basis for ICS superiority over LTRAs at asthma Step 2 is the breadth of anti-inflammatory mechanism. Asthma is driven by a complex, redundant inflammatory network involving mast cells, eosinophils, Th2 lymphocytes, basophils, innate lymphoid cells type 2 (ILC2), dendritic cells, and airway epithelial cells, releasing multiple parallel pro-inflammatory mediators: histamine, cysteinyl leukotrienes, prostaglandin D2, cytokines (IL-4, IL-5, IL-13, thymic stromal lymphopoietin [TSLP]), eosinophil chemotactic factors, and epithelial-derived remodeling signals. Inhaled corticosteroids act at the level of the glucocorticoid receptor, producing broad transcriptional suppression via inhibition of NF-κB and AP-1 transcription factors; this reduces gene expression of the full spectrum of inflammatory mediators, cytokines, adhesion molecules, and enzymes across all participating cell types simultaneously. ICS also inhibit phospholipase A2 through lipocortin induction, reducing arachidonic acid liberation and thereby suppressing both the prostaglandin and leukotriene branches upstream. LTRAs, by contrast, block the CysLT1 receptor — a single downstream effector in one branch of one parallel inflammatory pathway. They leave histamine-mediated bronchoconstriction, prostaglandin D2 signaling, Th2 cytokine-driven eosinophilic recruitment, epithelial remodeling, and airway hyperresponsiveness driven by non-leukotriene mediators entirely unchecked. This mechanistic narrowness — not adherence, route, or pharmacokinetics — is the fundamental pharmacological reason LTRAs cannot match ICS in controlling the full spectrum of asthma inflammation.

• Option B: Option B is incorrect because the efficacy gap between LTRAs and ICS reflects mechanistic breadth, not route of administration; oral administration of an agent with broad anti-inflammatory coverage could be therapeutically equivalent to inhaled therapy, and the LTRA-ICS gap in clinical trials is not primarily a bioavailability issue; there are no inhaled LTRAs in advanced clinical development that have closed this gap.
• Option C: Option C is incorrect because ICS do not provide direct bronchodilation as a primary mechanism; ICS upregulation of beta-2 receptor expression is a modest secondary effect and is not the primary driver of the clinical superiority over LTRAs at Step 2; the mechanistic basis is anti-inflammatory breadth, not bronchodilation.
• Option D: Option D is incorrect because montelukast is a once-daily agent — not twice-daily — so the adherence argument based on dosing frequency does not apply; zafirlukast is twice daily, but the ICS superiority over LTRAs is demonstrated in controlled per-protocol trials where adherence is equalized, confirming that the efficacy gap is pharmacological, not behavioral.
• Option E: Option E is incorrect because the efficacy inferiority of LTRAs relative to ICS is not explained by tissue penetration or free-drug concentrations at CysLT1 receptors; montelukast achieves effective CysLT1 occupancy as confirmed by its documented efficacy in EIB (exercise-induced bronchoconstriction) and AERD; the limitation is not receptor occupancy but the restricted scope of the target pathway relative to asthma's multi-mediator pathophysiology.

ANSWER: C

Rationale:

This scenario illustrates how two independent pathophysiological processes can simultaneously converge on the same pharmacokinetic vulnerability — CYP1A2-mediated theophylline clearance — producing compounded toxicity risk that is substantially greater than either condition would generate alone. Acute decompensated heart failure reduces cardiac output and consequently reduces hepatic blood flow; diminished hepatic perfusion impairs CYP1A2-mediated theophylline extraction, reducing clearance and elevating steady-state concentrations at an unchanged dose. Febrile viral illness — particularly influenza — transiently suppresses CYP1A2 enzymatic activity through interferon-mediated downregulation of CYP gene expression; interferons produced in response to viral infection reduce CYP1A2 transcription and translational efficiency, further impairing theophylline metabolism. When both mechanisms are active simultaneously in a patient whose baseline level is 13 mcg/mL — already positioned near the saturation threshold where Michaelis-Menten kinetics begin to produce disproportionate concentration accumulation with small reductions in clearance — the pharmacokinetic consequences are compounded. A patient near the saturation threshold who experiences even a moderate reduction in CYP1A2 capacity can undergo rapid, non-linear concentration escalation well into the toxic range within 24–48 hours without any dose change. This mechanistic synthesis — Michaelis-Menten kinetics at the threshold, combined with two independent clearance-reducing pathophysiological processes — explains why this scenario carries particularly high toxicity risk.

• Option A: Option A is incorrect because interferon produced during viral illness does not upregulate CYP1A2 — it downregulates it; interferon-mediated CYP1A2 suppression reduces theophylline clearance and raises serum concentrations; and pulmonary edema does not increase theophylline's volume of distribution in a manner that would lower plasma concentrations — theophylline Vd is relatively stable and not substantially altered by pulmonary fluid redistribution.
• Option B: Option B is incorrect because influenza infection does not activate P-glycoprotein-mediated theophylline efflux from hepatocytes; theophylline is not a clinically significant P-glycoprotein substrate, and this mechanism does not exist as described; the two effects are not opposing — both CHF and febrile viral illness reduce theophylline clearance through distinct mechanisms, making the direction of concentration change unambiguously upward.
• Option D: Option D is incorrect because histamine released during mast cell degranulation does not competitively displace theophylline from adenosine A1 receptors; histamine acts at H1 and H2 receptors, not adenosine receptors; the pharmacodynamic interaction described does not represent an established mechanism of theophylline toxicity potentiation.
• Option E: Option E is incorrect because while hepatic venous congestion does contribute to reduced hepatic drug metabolism in CHF, characterizing it as the "sole" mechanism excludes the important contribution of reduced hepatic blood flow and CYP1A2 activity more broadly; and fever-driven peripheral vasodilation does not significantly increase theophylline's apparent volume of distribution or dilute plasma levels to produce misleadingly low readings — the primary pharmacokinetic effect is on hepatic clearance, not distribution.

ANSWER: E

Rationale:

Cromolyn's near-total displacement by ICS in adult and pediatric asthma reflects the accumulated evidence that ICS provides superior efficacy across virtually all asthma severity levels and patient populations. However, cromolyn retains a pharmacologically coherent — if narrow — niche in specific pediatric contexts where the particular clinical priorities shift the benefit-risk calculus. Its defining pharmacological advantage is its virtually absent systemic absorption: inhaled cromolyn is not meaningfully absorbed from the airway, producing no HPA (hypothalamic-pituitary-adrenal) axis suppression, no growth effects, no adrenal suppression risk, and no systemic immunosuppression. In very young children — particularly infants and toddlers — where the dose-response relationship between low-dose ICS and growth effects is still being delineated longitudinally, or in patients with significant recurrent oral candidiasis from inhaled steroid formulations, or in specific settings where any systemic corticosteroid exposure is particularly undesirable, cromolyn's local-only mechanism and established pediatric safety record provide genuine clinical justification for its use as an alternative. This does not mean cromolyn equals ICS in efficacy — it does not — but for families and clinicians where ICS concerns are real and persistent, cromolyn represents a pharmacologically honest alternative with a distinctive and well-understood safety profile.

• Option A: Option A is incorrect because cromolyn is not used at GINA Step 4 or above; its clinical role has contracted to very limited circumstances, not expanded to severe persistent asthma where high-dose ICS and add-on biologics are the standard; and the claim of synergistic eosinophil suppression with high-dose ICS in the combination is not supported by established evidence.
• Option B: Option B is incorrect because cromolyn's mechanism — chloride channel blockade on mast cell membranes — does not specifically inhibit the 5-LOX pathway; cromolyn prevents mast cell degranulation, but it does not directly inhibit leukotriene synthesis; LTRA therapy with montelukast or zileuton is the pharmacologically appropriate leukotriene-targeted intervention in AERD, not cromolyn.
• Option C: Option C is incorrect because ICS are not relatively contraindicated across the pediatric age group; ICS remain the preferred first-line controller at GINA Step 2 and above in children as well as adults; the HPA suppression risk from low-dose ICS in children is real but manageable with appropriate dose selection and monitoring, and this risk does not make ICS relatively contraindicated; cromolyn does not provide equivalent efficacy to ICS.
• Option D: Option D is incorrect because the absence of a boxed warning is not a regulatory basis for designating cromolyn as a required intermediate step before ICS in pediatric patients; GINA and standard pediatric asthma guidelines do not position cromolyn as a mandatory escalation step between montelukast failure and ICS initiation; this option misrepresents both regulatory framework and guideline-based step therapy.

ANSWER: B

Rationale:

The mechanistic distinction between zileuton and montelukast in neutrophil-dominant airway inflammation rests entirely on LTB4. LTB4 is the dominant leukotriene mediator of neutrophil recruitment and activation in COPD: it acts through BLT1 (leukotriene B4 receptor 1) receptors on neutrophils, driving chemotaxis, priming, degranulation, and sustained presence in the airway. LTB4 also signals through BLT2 receptors on mast cells and eosinophils. Critically, LTB4 does not signal through CysLT1 receptors — it uses a completely separate receptor family (BLT1/BLT2) with distinct signaling characteristics. Montelukast, as a CysLT1-selective antagonist, has no pharmacological activity at BLT1 or BLT2 receptors; it therefore cannot affect LTB4-driven neutrophil chemotaxis or activation in any way. In a patient with sputum neutrophilia, the dominant inflammatory driver is LTB4 acting through BLT receptors — a pathway entirely outside montelukast's pharmacological reach. Zileuton, by inhibiting 5-LOX upstream of the LTA4 branch point, reduces synthesis of all leukotrienes simultaneously: both LTB4 (through reduced LTA4 hydrolase substrate availability) and the cysteinyl leukotrienes (through reduced LTC4 synthase substrate availability). In neutrophil-dominant disease, only 5-LOX inhibition addresses the relevant inflammatory pathway; CysLT1 antagonism is mechanistically irrelevant to LTB4-driven neutrophilia.

• Option A: Option A is incorrect because CysLT1 receptors are not expressed at high density on neutrophils in a pharmacologically meaningful way for LTB4 signaling — LTB4 signals through BLT1/BLT2, not CysLT1; the claim that CysLT1 blockade addresses neutrophil recruitment more effectively than 5-LOX inhibition inverts the correct mechanistic relationship.
• Option C: Option C is incorrect because LTB4 and the cysteinyl leukotrienes do not converge on the same intracellular signaling cascade in neutrophils; LTB4 signals through BLT1 (Gi-coupled, distinct intracellular cascades) while cysteinyl leukotrienes signal through CysLT1 (Gq-coupled); montelukast's CysLT1 blockade does not substitute for LTB4/BLT1 pathway suppression in neutrophilic disease.
• Option D: Option D is incorrect because zileuton does not inhibit COX-1; it is a selective 5-LOX inhibitor with no direct COX enzyme activity; the described mechanism of COX-1 inhibition promoting neutrophil apoptosis through PGE2 suppression attributes aspirin-like pharmacology to zileuton, which is pharmacologically inaccurate.
• Option E: Option E is incorrect because LTB4 is well established as a major driver of neutrophilic airway inflammation in COPD, not merely a secondary mediator; while IL-8 (CXCL8) is also an important neutrophil chemoattractant in COPD, the two pathways are not mutually exclusive and LTB4's contribution through BLT1 signaling is substantial and specifically addressable by 5-LOX inhibition; characterizing both agents as equivalent through a non-specific class effect dismissal is pharmacologically unsupported.

ANSWER: D

Rationale:

Pre-exercise albuterol and daily montelukast address EIB (exercise-induced bronchoconstriction) through distinct and complementary mechanisms with different temporal profiles. Albuterol is a beta-2 adrenergic agonist that prevents EIB by causing rapid airway smooth muscle relaxation through Gs-protein-coupled adenylyl cyclase activation, raising cAMP and activating protein kinase A to phosphorylate myosin light chain kinase; this protection has a rapid onset and is highly effective but is time-limited — approximately four to six hours — and does not address mediator release from mast cells triggered by exercise-induced airway cooling and hyperosmolarity. During exercise, mast cells in the airway mucosa degranulate in response to exercise-driven stimuli, releasing cysteinyl leukotrienes (LTC4, LTD4, LTE4) that produce bronchoconstriction via CysLT1 receptors on airway smooth muscle — a mechanistic contribution that is partially resistant to beta-2 agonist reversal, explaining why some patients have breakthrough EIB despite adequate SABA use. Montelukast blocks CysLT1 receptors throughout the 24-hour dosing interval, suppressing both the early leukotriene-driven bronchoconstriction component and the late-phase inflammatory response that can cause rebound symptoms hours after exercise. For a competitive swimmer with prolonged training sessions — where albuterol's duration of protection may be outlasted — and breakthrough EIB despite reliable SABA use, adding montelukast addresses a distinct mechanistic pathway that SABA does not cover.

• Option A: Option A is incorrect because montelukast does not raise cAMP — it blocks CysLT1 receptors coupled through Gq (not cAMP-dependent signaling); the mechanisms of SABA and LTRA are not pharmacologically redundant; CysLT1 blockade does not modulate phosphodiesterase activity; the two agents address entirely different effector pathways.
• Option B: Option B is incorrect because montelukast is a CysLT1 receptor antagonist, not a mast cell stabilizer with chloride channel blocking activity — that is cromolyn's mechanism; and EIB is mediated by cysteinyl leukotrienes released from exercise-activated mast cells, not primarily by histamine; IgE-mediated sensitivity confirmation by skin testing is not required before using montelukast for EIB.
• Option C: Option C is incorrect because montelukast's FDA approved indications for EIB do not restrict its use to patients who cannot use inhaled SABA due to physical limitations; it is indicated for the prevention of EIB in patients aged 15 and older as an approved indication, without a restriction requiring SABA unavailability; combination use with SABA is clinically appropriate and pharmacologically rational.
• Option E: Option E is incorrect because the clinical benefit of montelukast in EIB is not restricted to atopic patients with measurably elevated urinary LTE4; multiple controlled trials demonstrate benefit from montelukast in EIB across patient populations, and the requirement for LTE4 biomarker confirmation before prescribing does not represent clinical practice or established prescribing criteria; the claim that cysteinyl leukotrienes are not a dominant mediator in non-atopic EIB oversimplifies the complex mediator biology of exercise-triggered airway responses.

ANSWER: A

Rationale:

This case illustrates one of the most clinically critical features of aspirin desensitization: the tolerant state is not permanent and reverses within days of aspirin discontinuation. The mechanism of the desensitized state involves CysLT1 receptor downregulation on mast cells and eosinophils, reduced responsiveness of these cells to CysLT1 signaling, and possible EP2 receptor upregulation — all of which depend on the continuous pharmacological presence of aspirin to be maintained. When aspirin is held for three days, these pharmacological adaptations reverse, and the airway mast cells and eosinophils return toward their baseline AERD phenotype: constitutively elevated 5-LOX activity with reduced PGE2-mediated inhibitory tone via EP2 receptors. When aspirin is then resumed — regardless of what the dose was during the maintained desensitized phase — the COX-1 inhibition produced by the first post-cessation dose is pharmacologically equivalent to an aspirin challenge in a fully AERD-sensitized patient, triggering the same PGE2 withdrawal, arachidonic acid shunting to 5-LOX, and cysteinyl leukotriene surge that occurs in any naïve AERD patient given aspirin for the first time. The clinical reaction she experienced is the expected and mechanistically predictable consequence of desensitization reversal. The correct clinical response is repeat aspirin desensitization at a specialized center before aspirin can be safely resumed. This case also highlights the need for AERD-aware perioperative planning: in patients requiring aspirin for cardiovascular indications who have been desensitized, the aspirin hold must be justified by a clear benefit-risk calculation, with a pre-planned repeat desensitization pathway if the hold is unavoidable.

• Option B: Option B is incorrect because the reversal of desensitization does not produce rebound CysLT1 receptor upregulation above pre-treatment baseline levels; the physiology returns toward baseline AERD, not to a hypersensitized state above it; and repeat desensitization is not permanently contraindicated — it is in fact the required clinical response and can be performed safely at an experienced center.
• Option C: Option C is incorrect because the question stem does not mention ketorolac in the intraoperative protocol and introduces a speculative additional mechanism not supported by the clinical information given; the pharmacological explanation for the reaction is entirely explained by aspirin desensitization reversal during the three-day hold, without requiring an additional ketorolac-triggered priming event; and recommending permanent aspirin avoidance contradicts the established management approach for this patient who requires aspirin for coronary artery disease.
• Option D: Option D is incorrect because montelukast does not maintain aspirin desensitization during aspirin holds; the desensitized state is dependent on continuous aspirin, not on concurrent LTRA therapy; CysLT1 tachyphylaxis driven by inflammation is not a recognized mechanism of montelukast efficacy loss; and increasing montelukast dose does not substitute for repeat aspirin desensitization.
• Option E: Option E is incorrect because aspirin 650 mg twice daily is a standard and appropriate maintenance dose after desensitization, not an above-threshold dose; the mechanism of desensitization maintenance does not involve beta-2 adrenergic receptor downregulation — it involves CysLT1 downregulation and EP2 upregulation through continuous COX-1 inhibition; and resuming aspirin at 81 mg daily after a three-day hold would trigger the same reaction as any other dose, since the patient is no longer desensitized regardless of the dose level.